PLx Pharma Inc. Common Stock
PLXP
PLXP was delisted on the 12th of April, 2023.
19 hedge funds and large institutions have $7.95M invested in PLx Pharma Inc. Common Stock in 2018 Q2 according to their latest regulatory filings, with 4 funds opening new positions, 3 increasing their positions, 3 reducing their positions, and 2 closing their positions.
100% more first-time investments, than exits
New positions opened: 4 | Existing positions closed: 2
14% more capital invested
Capital invested by funds: $6.98M → $7.95M (+$975K)
12% more funds holding
Funds holding: 17 → 19 (+2)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0% more repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 3
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wells Fargo
San Francisco,
California
|
+$44.9K |
| 2 |
PAM
Panagora Asset Management
Boston,
Massachusetts
|
+$7.64K |
| 3 |
Renaissance Technologies
New York
|
+$4.49K |
| 4 |
BlackRock
New York
|
+$1.89K |
| 5 |
SPIA
Steward Partners Investment Advisory
New York
|
+$306 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
6CM
683 Capital Management
New York
|
-$73K |
| 2 |
CH
CVI Holdings
Wilmington,
Delaware
|
-$68.7K |
| 3 |
UBS Group
Zurich,
Switzerland
|
-$8.81K |
| 4 |
RJA
Raymond James & Associates
St Petersburg,
Florida
|
-$6.87K |
| 5 |
TRCT
Tower Research Capital (TRC)
New York
|
-$2K |
PLXP Hedge Fund Activity: Q2 2018 in Review
19 of the 4,368 institutional investors tracked by Wall St. Rank reported a position in PLx Pharma Inc. Common Stock (PLXP) for Q2 2018, worth a combined $7.95M — up 14% from $6.98M a quarter earlier.
Buyers outnumbered sellers: 4 funds opened new PLXP positions and 2 closed out — a net gain of 2 holders — while 3 added to existing stakes and 3 trimmed.
The largest buyer was Wells Fargo, opening a new position worth an estimated $44.9K. The largest seller was 683 Capital Management, exiting entirely with an estimated $73K sold.
- 19 institutional investors held PLx Pharma Inc. Common Stock (PLXP) as of Q2 2018, up from 17 in Q1 2018.
- Funds reported $7.95M of PLx Pharma Inc. Common Stock stock for Q2 2018, up 14% quarter-over-quarter.
- 4 funds opened new PLx Pharma Inc. Common Stock positions in Q2 2018 and 2 closed out, a net change of +2 holders.
- The largest PLx Pharma Inc. Common Stock buyer in Q2 2018 was Wells Fargo, an estimated $44.9K added.
- The largest PLx Pharma Inc. Common Stock seller in Q2 2018 was 683 Capital Management, an estimated $73K sold.
Based on aggregated 13F filings for Q2 2018.